Pharmaceutical giants like Lilly and Nordisk are battling for dominance in India’s weight-loss market with price cuts and ...

ChatGPT builds a $1,000 stock portfolio for 2026, highlighting Microsoft, Nvidia, energy and defence stocks positioned for AI growth and market uncertainty.

The magazine’s most-read articles of the year included a deep dive on the Scopes "monkey trial," an interview with ...

The FDA is expected to issue a decision on Vanda’s Tradipitant, a motion-sickness treatment aimed at preventing vomiting, on ...

ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, announced that ABL Bio will receive a USD 40 million upfront payment for the license, research and collaboration agreement ...

U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The U.S. Food and Drug Administration’s ...

Major stock indexes ended higher for a fourth straight session Tuesday, with the S&P 500 setting a fresh closing record, ...

But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study. And through the first nine months of 2025, Zepbound generated $9.3 billion ...

A major health care divide is coming in 2026. Some Americans may finally catch a break on rising costs, as the first ...

Wall Street closed higher and reached more records Wednesday on a holiday-shortened trading day. The S&P 500 index rose 22.26 ...

Asian shares are mixed in thin holiday trading, with most markets in the region and elsewhere closed for Christmas ...

About 14% of adults in Philadelphia have diabetes, one of the highest rates in the country, the city said, and Black and ...